Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Absorptiometry, Photon

Mulligan K, Parker RA, Komarow L, et al. "Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial." J. Acquir. Immune Defic. Syndr.. 2006;41(5):590-7.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.
Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
Erlandson KM, Kitch D, Tierney C, et al. "Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density." AIDS. 2013;27(13):2069-79.
Overton ETurner, Chan ES, Brown TT, et al. "Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial." Ann. Intern. Med.. 2015;162(12):815-24.
McComsey GA, Kendall MA, Tebas P, et al. "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV." AIDS. 2007;21(18):2473-82.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.

Accidental Falls

Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.

Acquired Immunodeficiency Syndrome

Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. "Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis." J. Acquir. Immune Defic. Syndr.. 2007;46(4):402-9.
Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. "Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms." AIDS. 2013;27(6):967-72.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. "Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177." J. Acquir. Immune Defic. Syndr.. 2010;54(4):e7-9.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Gange SJ, Kitahata MM, Saag MS, et al. "Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)." Int J Epidemiol. 2007;36(2):294-301.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
Motsinger AA, Ritchie MD, Shafer RW, et al. "Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study." Pharmacogenet. Genomics. 2006;16(11):837-45.
Messer K, Vaida F, Hogan C. "Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217." Contemp Clin Trials. 2006;27(6):506-17.
George E, Noël F, Bois G, et al. "Antiretroviral therapy for HIV-1-infected children in Haiti." J. Infect. Dis.. 2007;195(10):1411-8.

Pages